Although numerous technical advances have been made in cancer treatment, chemotherapy is still a viable treatment option. However, it is more effective when used in combination with photothermal therapy for resistant breast cancer cells. This study introduces a smart drug delivery system, (DOX-OA+VERA+AuNRs)@NLC, which is designed for dual chemo/photothermal therapy of multiple-drug-resistant breast cancer. Type-III nanostructured lipid carriers (NLCs) were used as drug delivery systems, where nano-in-nano structures offer several advantages. Doxorubicin (DOX) was used as the antitumor agent by ion-pairing it with oleic acid (OA) to increase the DOX loading capacity, as well as to reduce the burst release of the drug. Verapamil (VERA), which was used as a chemosensitizer to overcome the multiple-drug resistance, was co-loaded with DOX-OA. Gold nanorods (AuNRs) were exploited as the photothermal therapy agent in photothermal therapy (PTT) application, which would have a synergistic relation with chemotherapy. The release of DOX-OA and VERA from NLCs was studied by triggering with NIR laser irradiation. Thus, an all-in-one drug delivery system was designed to release the active pharmaceutical ingredients (APIs) at higher concentrations in the desired region and provide both chemo/PTT. Besides, the application of a folic acid-chitosan (FA-CS) coating to NLCs has facilitated the development of systems capable of targeting and specifically releasing their cargo within cancerous tissues while preserving their surrounding environment.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsabm.4c01675DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
photothermal therapy
12
drug delivery
12
nanostructured lipid
8
lipid carriers
8
delivery system
8
therapy
5
chemosensitizer loaded
4
loaded nir-responsive
4
nir-responsive nanostructured
4

Similar Publications

Importance: Frailty assessed at a single time point is associated with mortality in older women with breast cancer. Little is known about how changes in frailty following cancer treatment initiation affect mortality.

Objective: To evaluate the association between claims-based frailty trajectories following adjuvant chemotherapy initiation and 5-year mortality in older women with stage I to III breast cancer.

View Article and Find Full Text PDF

Purpose: The FAST-Forward study paved the way for ultrahypofractionation (UHF) in breast cancer. We prospectively registered and analyzed our case series receiving UHF + simultaneous integrated boost (SIB) to further reduce the treatment to a total of 5 days. The study aimed to present the 6-month early side effects results of the first patients treated with this scheme in 16 radiation oncology centers in Spain.

View Article and Find Full Text PDF

Objective: Persistent postoperative sensory loss significantly limits breast reconstruction following mastectomy. In addition, the absence of sensation profoundly impacts patients' physical well-being and overall quality of life. New surgical techniques involving nerve autograft intercostal nerve elongation have been introduced to neurotize reconstructed breasts.

View Article and Find Full Text PDF

Endometriosis and cancer risk.

Eur J Cancer Prev

March 2025

Department of Oncology and Hemato-Oncology, University of Milan.

Endometriosis is one of the most common gynecological benign disease. Epidemiological evidence suggests a potential association between endometriosis and cancer risk. Accumulating evidence highlighted the risk of ovarian cancer, particularly endometrioid and clear cell subtypes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!